A Prospective,Multi-center,Cohort Trial: the Efficacy and Safety of Tenofovir Alafenamide Fumarate Tablets (TAF) in Blocking Mother-to-child Transmission of Hepatitis B Virus(HBV)
Overview
- Phase
- Not Applicable
- Intervention
- Tenofovir Alafenamide Fumarate tablets
- Conditions
- Hepatitis B Virus
- Sponsor
- Southeast University, China
- Enrollment
- 330
- Locations
- 1
- Primary Endpoint
- MTCT rates in the TAF treated mothers
- Last Updated
- 6 years ago
Overview
Brief Summary
This study is a single-group, multi-center and prospective clinical study designed to assess the efficacy and safety of TAF in blocking mother-to-child transmission of hepatitis B virus.Pregnant women whose HBsAg and HBeAg are positive are included in the study.Eligible hepatitis B pregnant women are given TAF antiviral therapy at 24-28 weeks of gestation to block mother-to-child transmission and followed up during pregnancy and after delivery.The study will be initiated with approval by the central ethics committee.Subjects will start screening after signing the informed consent form. Those who meet the criteria will start taking TAF (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.At that time, chronic hepatitis B carrier will stop taking antiviral therapy, and patients with chronic hepatitis B decide whether to continue the therapy according to the patient's condition.The babies born are immunized according to the national standard immunization program,, that is, 100 IU of hepatitis B immunoglobulin (HBIG) and 10 μg/0.5 ml of hepatitis B vaccine are given within 12 hours after birth. And the same dose of hepatitis B vaccine is given at 1 month and 6 months of age.
Investigators
Guo-rong Han
Director of Obstetrics and Gynecology
Southeast University, China
Eligibility Criteria
Inclusion Criteria
- •maternal age: 20 to 35 years
- •20-24 week of gestation
- •HBsAg-positive more than 6 months and HBeAg-positive
- •HBV DNA\> 1000,000 IU/ml
- •both husband and wife voluntarily sign informed consent
- •with good compliance and comply with follow-up programs
Exclusion Criteria
- •mother with co-infection of hepatitis C virus,human immunodeficiency virus
- •evidence of decompensated liver disease
- •combined with important organ lesions which will affect patient compliance and follow-up plans, pregnant women who are expected to be difficult to complete the study
- •have a history of spontaneous abortion, or have a birth defect or congenital malformation in the last pregnancy
- •mother treated with antiviral therapy within 6 months prior to enrollment(except those treated with antiviral therapy in the last pregnancy to prevent mother-to-child transmission)
- •have a history of kidney injury, creatinine clearance \<50ml/min, urine protein positive (\>300mg/L)
- •combined with other chronic diseases and need to take immunomodulators, cytotoxic drugs or hormonal drugs during pregnancy
- •the infants' biologic father is a chronic HBV infected person
- •symptoms of threatened abortion during early pregnancy
- •evidence of hepatic cell carcinoma
Arms & Interventions
TAF antiviral therapy group
Intervention: Tenofovir Alafenamide Fumarate tablets
Outcomes
Primary Outcomes
MTCT rates in the TAF treated mothers
Time Frame: 28 weeks post-partum
detectable levels of HBV DNA or HBsAg in the peripheral serum samples of infants at age 28 weeks